Chicago-Whether chemotherapy may benefit men with locally advanced prostate cancer is still not known, but it is hoped that clinical trials currently under way may provide some evidence on the potential role of adjuvant or neoadjuvant chemotherapy in this setting.
Chicago-For men diagnosed with early prostate cancer or localized disease, the roles of the urologist, surgical oncologist, and radiation oncologist have been fairly well defined. The role of medical oncologists in managing patients in the early stages of the disease is less clear.
Chicago-With the evolving definition of advanced prostate cancer that now includes a number of clinical states not previously defined, treatment has also evolved into a multimodal approach. This mandates close cooperation among urologists and medical and radiation oncologists to ensure optimal patient care, according to leading oncologists.
Chicago-One of the most difficult issues in the management of prostate cancer is identifying which men with indolent disease are at increased risk of progressing to more advanced disease. Reliance on traditional clinical prognostic factors, including PSA, has provided some guidance on treatment, but all too often, men with indolent disease are over-treated based on an incomplete knowledge of disease risk.
Cleveland-Although their data show otherwise, a group of researchers at the University of Rochester (NY) Medical Center have faith that using a cautery-free approach with Weck clips to preserve the neurovascular bundle during robot-assisted prostatectomy is a better choice than bipolar cautery.
Cleveland-Preoperative transrectal ultrasound biopsies are not always reliable tools for predicting positive surgical margins and tumor location in nerve-sparing robotic radical prostatectomies. However, this unreliability may be partly due to the biopsy results coming from outside labs and pathologists versus in-house evaluations.
Cleveland-Intraprostatic injection of mepivacaine epinephrine through a specialized catheter reduces the need for analgesia, as well as treatment time and energy consumption in patients undergoing high-energy transurethral microwave thermotherapy (TUMT) for BPH, researchers reported here.
Beginning in 1998, consensus conferences concerning the grading of urothelial cancer addressed removal of the word "carcinoma" from low-grade papillary tumors with little or no malignant potential. The subsequent change in terminology has been controversial, however, and many pathologists as well as most urologists continue to use the traditional three-grade classification system.
Cleveland-Which approach to radical nephrectomy produces the most durable outcomes in survival and restored renal function: laparoscopy or open surgery?
National Report-With another year of Medicare payment cuts looming in 2007, declining reimbursement is no surprise as the number one current concern among practicing urologists, according to an exclusive survey from Urology Times and its sister publication, Contemporary Urology. Changes in reimbursement are followed closely by malpractice, office overhead, pay for performance, and increasing regulations as the top five issues that urologists are extremely or very concerned about, the first State of the Specialty survey found.
Ankara, Turkey-Elevated PSA levels and the presence of urinary tract infection are the symptomatic parameters that are most predictive of acute urine retention in men with BPH, according to a group of Turkish researchers. Their data also suggest that plasmakinetic resection of the prostate may provide 1-year outcomes similar to those of open prostatectomy in BPH patients who do not have retention.
Cleveland-Understaging of renal tumors on the basis of clinical criteria appears problematic when tumors are morcellated during laparoscopic nephrectomy, according to a Mayo Clinic study presented at the 2006 World Congress of Endourology here.
We must increase the number of, and accrual to, clinical trials. The best way is in the setting of multidisciplinary clinics.
Men with overactive bladder and lower urinary tract symptoms who receive combination therapy are more likely to report improvement in symptoms than those who receive only one medication, according to results of a study recently reported in JAMA (2006; 296:2319-28).
The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder.
Three new staff members have joined the Cleveland Clinic Glickman Urological Institute: Jeffrey Palmer, MD, is the director of minimally invasive surgery, pediatric urology; Courtenay K. Moore, MD, is a specialist in female urology; and Edmund Sabanegh, MD, is head of the section of male infertility.
Peter R. Carroll, MD, has been appointed director of clinical services and strategic planning of the University of California, San Francisco Comprehensive Cancer Center and associate dean of the UCSF School of Medicine.
Vardenafil (Levitra) appears to be effective at first dose, with continued success in treating erectile dysfunction in men with associated medical conditions, including hypertension, diabetes, and dyslipidemia, the authors of a Canadian study report.
Treatment with anti-thymocyte globulin (rabbit [Thymoglobulin]) results in a significantly reduced risk of acute rejection and acute rejection requiring antibody therapy and a similar risk of delayed graft function, graft loss, and death in kidney transplant patients compared with patients receiving induction therapy with basiliximab (Simulect), according to a study published this month in the New England Journal of Medicine (2006; 355:1967-77).
Topiramate (Topamax), a drug commonly prescribed to treat seizures and migraines, can increase the propensity for calcium phosphate kidney stones, according to a study by researchers at the University of Texas Southwestern Medical Center in Dallas.
A coalition of prostate cancer advocacy groups has issued a call for Medicare to drop its least costly alternative (LCA) policy of for prostate cancer patients.
Men with overactive bladder and lower urinary tract symptoms who receive combination therapy are more likely to report improvement in symptoms than those who receive only one medication, according to results of a study recently reported in JAMA (2006; 296:2319-28).
PSA velocity is an accurate gauge of prostate tumor aggression and danger, even when PSA levels are so low as to not warrant a biopsy, according to researchers at the Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore.
Diagnostic Ultrasound Corp. has updated its company name to Verathon, Inc. (Bothell, WA).
Timm Medical said the FDA has allowed the company to extend the labeling of its Osbon ErecAid device for use in creating and maintaining erections by providing arterial blood to the penis during recovery from radical prostatectomy.
Firefighters in five Rhode Island communities are being offered free screening for bladder cancer in a voluntary program paid for and sponsored by their local state representatives.
Two consumer advocacy groups have joined with the Surgical Care Improvement Project (SCIP) to improve patient safety during surgery and increase communication between patients and their caregivers.
New guidelines, one set for adults and one for children, have been developed to help physicians reduce the occurrence of postoperative nausea and vomiting.
New explanatory analyses of a phase III study support earlier results observed with treatment using the investigational active cellular immunotherapy sipuleucel-T (Provenge) in men with advanced androgen-independent prostate cancer, researchers reported at the Prostate Cancer Foundation's annual scientific retreat in Scottsdale, AZ.
The National Cancer Institute has released new data from the Cancer Genetic Markers of Susceptibility study on prostate cancer that may help identify genetic factors that influence the disease and will be integral to the discovery and development of new targeted therapies.